Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUVAX Alzheimer's Vaccine in Healthy Volunteers
NCT07142278Phase 1Recruiting
- Sponsor
- Nuravax
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DUVAX in Alzheimer's disease (AD) (3 arms), sponsored by Nuravax. Primary endpoint: Treatment-Emergent Adverse Events at 74 weeks. Started Sep 2026; status: recruiting.
02
Drugs
DUVAX
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07142278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142278.